Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 12941 | 359.37 |
09:34 ET | 14183 | 357.1 |
09:36 ET | 200 | 357.925 |
09:38 ET | 300 | 359.37 |
09:41 ET | 100 | 359.105 |
09:45 ET | 957 | 359.02 |
09:48 ET | 100 | 359.515 |
09:56 ET | 100 | 359.815 |
09:59 ET | 200 | 359.955 |
10:01 ET | 100 | 360.21 |
10:06 ET | 1333 | 360.37 |
10:10 ET | 200 | 360.37 |
10:12 ET | 230 | 360.37 |
10:14 ET | 200 | 360.37 |
10:17 ET | 1213 | 359.955 |
10:19 ET | 224 | 359.605 |
10:21 ET | 600 | 360 |
10:24 ET | 100 | 359.39 |
10:28 ET | 2701 | 359.54 |
10:30 ET | 300 | 359.645 |
10:37 ET | 600 | 360.27 |
10:39 ET | 307 | 360.285 |
10:48 ET | 500 | 360.1049 |
10:50 ET | 1100 | 359.7 |
10:51 ET | 100 | 359.84 |
11:02 ET | 810 | 359.98 |
11:04 ET | 500 | 359.845 |
11:09 ET | 705 | 359.8 |
11:11 ET | 100 | 359.56 |
11:13 ET | 500 | 359.595 |
11:15 ET | 100 | 359.6 |
11:18 ET | 200 | 359.985 |
11:22 ET | 301 | 359.79 |
11:24 ET | 630 | 359.805 |
11:27 ET | 851 | 359.35 |
11:31 ET | 100 | 358.96 |
11:42 ET | 100 | 358.345 |
11:51 ET | 202 | 358.27 |
11:56 ET | 100 | 358.275 |
12:03 ET | 100 | 357.69 |
12:05 ET | 100 | 357.96 |
12:09 ET | 100 | 357.69 |
12:12 ET | 100 | 358.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 15.1B | 16.5x | +8.22% |
Biomarin Pharmaceutical Inc | 16.2B | 53.1x | --- |
Exact Sciences Corp | 12.1B | -69.5x | --- |
Neurocrine Biosciences Inc | 12.3B | 34.7x | +62.04% |
Qiagen NV | 10.4B | 142.0x | +12.66% |
Medpace Holdings Inc | 10.9B | 31.1x | +35.10% |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.1B |
---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $21.75 |
Book Value | $127.23 |
P/E Ratio | 16.5x |
Price/Sales (TTM) | 5.8 |
Price/Cash Flow (TTM) | 13.4x |
Operating Margin | 48.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.